When: Price closes below $357.77 (lower Bollinger Band) on volume >2.5M shares

Then: Exit the session rather than waiting for $340 stop

HOLD with tightened risk controls: reduce position 20-25%, tighten stop to $350, no adding below $383 without Q3 confirmation

• Working capital drag of $248M in Q2 from inventory build of +22% vs revenue +18.5% is a real cash outflow
• Receivables up 27% year-over-year, outpacing revenue growth, could signal channel stuffing or end-demand softening
• 30.6x forward multiple requires mid-teens revenue growth and 25%+ EPS expansion in a higher-rate regime where historical 45x multiple was earned under ZIRP
• Modest growth deceleration to 14-15% could compress multiple to mid-20s, implying $300-320 price target
• Medtronic's $700M Hugo investment is a 2027-2028 structural risk, not a quarterly event—competitive impact shows over years
• Technical setup: price below 10 EMA, 50 SMA, and 21% below 200 SMA with bearish moving average alignment
• MACD histogram turned negative 9/1 after brief positive run; lower highs since January suggest continued slide
• With beta 1.46 and ATR 11.7, a bad Q3 print could produce 15% gap down; $340 stop is insufficient protection
• Q3 faces 90 basis point comp headwind from 2.9% higher base ($2.51B vs $2.44B); needs $2.97B for 18.5% growth
• Probability-weighted scenario: 25% chance hits $540, 15% chance hits $600, 60% chance chop/grind lower
• Fat tail risk: Q3 disappointment with 22-25x re-rating implies $260-300, representing 25% downside from current levels

→ vs aggressive: The 45x historical forward multiple was earned under ZIRP and quantitative easing; Polymarket prices 89% odds of zero Fed cuts in 2026, making mean reversion to that multiple 'nostalgia' not a base case

→ vs aggressive: The 46-60% upside vs 8% downside framing assigns asymmetric probabilities that conveniently support the thesis; actual probability-weighted expected value favors the chop scenario at 60%

→ vs aggressive: Saying 'waiting for confirmation causes you to miss moves' is 'folklore that destroys wealth'; the current chart has made lower highs since January, not a coiled spring

→ vs aggressive: Tough comp 'already lapped' framing is incorrect; Q3 has a 90 basis point headwind from 2.9% higher base, and summer months are typically weak for elective procedures

→ vs aggressive: Da Vinci 5 ramp optimism is 'speculation dressed up as conviction' until ISRG breaks out actual placement numbers; alternative interpretation of inventory build (distributor stocking ahead of slower period) is equally plausible

HOLD with defined trade parameters: maintain current position weight, use $340 stop with conditional fast-exit at $357.77 lower Bollinger on expanding volume, and add only on confirmed 50 SMA reclaim at $383 with momentum confirmation

• Q3 needs ~$2.97 billion revenue to match Q2's 18.5% growth rate; consensus expects 16-18%
• Current price $369 with 50 SMA resistance at $383 and lower Bollinger band at $357.77
• 30.6x forward P/E is fair equilibrium given macro environment and competitive overhang, not mispriced
• Bull-case fair value revised to $420 (35x multiple) vs aggressive analyst's $540; still 15% upside from $369
• Bear-case fair value $260-300 at 22-25x multiple if Q3 prints 14-15% growth
• Inventory build is a yellow flag tied to da Vinci 5 pre-building, not channel stuffing; gross margin expanded to 67.8%
• $3.7 billion buybacks over 5 quarters on $132 billion market cap = 2.8% annual buyback rate providing structural floor
• Hospital capex budget cycle and summer elective procedure slowdown are real Q3 headwinds
• Conservative's $350 stop (1.6x ATR) is too tight and will get stopped out on routine noise; $340 (2x ATR) is better calibrated
• Q3 bear thesis confirmation (14-15% growth) should trigger 25-33% trim per trader's framework, not pre-emptive position reduction

→ vs aggressive: The 46% upside case assumes 45x multiple re-rating, but competitive overhang and restrictive macro keep the realistic bull-case multiple at 35x, yielding $420 fair value (14% upside), not $540; calling this asymmetric in favor with 60% upside probability is motivated reasoning

→ vs conservative: Labeling the inventory build as channel stuffing is overreach and weakens credibility; gross margin expansion to 67.8% alongside inventory growth indicates pricing power intact and product moving, not forced stuffing

→ vs conservative: Pre-emptive 20-25% position reduction double-counts risk since the trader's framework already calls for 25-33% trim on Q3 bear thesis confirmation; the existing rule is the correct asymmetric response

→ vs conservative: The $350 stop-loss is too tight at 1.6x ATR (~$11.70) and will get wicked out by routine noise given ISRG's 1.46 beta and the July 17th panic session volatility; $340 stop (2x ATR) is better calibrated to the volatility regime